HE4 and Risk Factors of Endometrial Cancer in Women with Abnormal Uterine Bleeding; Application of Accelerated Failure Time Models

AuthorHassan Karimien
AuthorMona Khoramien
AuthorAlireza Solimanzadehen
AuthorElham Shafieien
AuthorHosein Seidkhanien
AuthorRazhan Chehrehen
OrcidElham Shafiei [0000-0001-5689-5235]en
Issued Date2025-12-31en
AbstractBackground: Endometrial cancer (EC) is the leading cause of death from gynecologic cancers. Objectives: This study was executed to estimate the role of human epididymal protein 4 (HE4) levels in the prognosis and follow-up of EC. Methods: This registry-based, single-center retrospective cohort study was conducted on women with abnormal uterine bleeding (AUB) between March 15, 2022, and September 15, 2023, at a university hospital in Ilam, southwest Iran. The study applied accelerated failure time (AFT) models to a dataset of 38 women with AUB. Model performance was evaluated using Akaike’s information criterion (AIC) and visual assessment of Cox-Snell residuals. The HE4 concentrations > 140 g/L at admission were considered predictive of ovarian tumors. Results: In the adjusted model, the results of the Weibull model showed that HE4 (adjusted time ratio; 1.89 (95% CI: 1.30 - 2.19; P < 0.001) was the accelerated factor for progression to EC in women with AUB. Conclusions: Serum HE4 dosage seems to be a useful preoperative test for predicting EC outcomes in women with AUB.en
DOIhttps://doi.org/10.5812/ijcm-149040en
URIhttps://brieflands.com/journals/ijcm/articles/149040en
KeywordHuman Epididymis Protein 4en
KeywordHE4en
KeywordEndometrial Canceren
KeywordPrognostic Markeren
PublisherBrieflandsen
TitleHE4 and Risk Factors of Endometrial Cancer in Women with Abnormal Uterine Bleeding; Application of Accelerated Failure Time Modelsen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijcm-18-1-149040-publish-pdf.pdf
Size:
231.43 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF